Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271100 | 0.80 | CRHR1 (0.53) | CRHR1IDH1 | |
| SCHEMBL3271725 | 0.72 | CRHR1 (0.65) | CRHR1 | |
| SCHEMBL3271338 | 0.72 | TP53 (0.38) | CRHR1TP53 | |
| SCHEMBL2190389 | 0.71 | CRHR1 (0.72) | CRHR1 | |
| SCHEMBL5494540 | 0.70 | SMN1; SMN2 (0.34) | CRHR1TP53 | |
| SCHEMBL5487155 | 0.70 | TP53 (0.38) | CRHR1TP53P2RX7 | |
| SCHEMBL2191256 | 0.68 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5492086 | 0.65 | TP53 (0.36) | CRHR1TP53 | |
| SCHEMBL3440663 | 0.64 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL5498704 | 0.64 | TP53 (0.36) | CRHR1TP53P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | claimed |
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | disclosed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR1, NR3C2, CRHR2 | CRHR1 1/4885IDH1 1211/4885TP53 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.